The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSDI Group Regulatory News (SDI)

Share Price Information for SDI Group (SDI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.50
Bid: 68.00
Ask: 71.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.412%)
Open: 69.00
High: 69.50
Low: 69.00
Prev. Close: 69.50
SDI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Monmouth Scientific Limited & TVR

3 Dec 2020 07:00

RNS Number : 3481H
SDI Group PLC
03 December 2020
 

SDI Group plc

("SDI", the "Company" or the "Group")

(AIM: SDI)

 

Acquisition of Monmouth Scientific Limited

and Total Voting Rights

SDI Group plc, the AIM quoted Group focused on the design and manufacture of scientific and technology products for use in digital imaging and sensing control applications, is pleased to announce the acquisition on 2 December 2020 of Monmouth Scientific Limited ("Monmouth Scientific"), a UK manufacturer of biological safety cabinets, fume cupboards, laminar flow cabinets and cleanrooms (the "Acquisition"). Total consideration, including earnout, is forecast to be approximately £5.8 million, net of cash acquired.

 

Highlights:

· Monmouth Scientific specialises in providing controlled clean air environments for scientific, medical and other technical applications

· The company is currently benefiting from high levels demand for its solutions for COVID-19 testing infrastructure

· Expected to move to new larger purpose-built premises in 2022

· Acquisition expected to be immediately earnings enhancing

 

Ken Ford, Chairman of SDI said: "Monmouth Scientific is a further step in our Group growth strategy. It is a complementary fit with our stable of businesses providing laboratory equipment, and generates areas for potential growth. The Acquisition is expected to be immediately earnings enhancing. We are delighted to welcome David Pomeroy and his team into the Group."

 

About Monmouth Scientific

 

Monmouth Scientific specialises in the design, manufacture and service of clean air solutions for a variety of scientific, medical and other technical sectors, protecting the purity of the air for both the controlled activity and for the operator. Principal products are biological safety cabinets, fume cupboards, laminar flow cabinets, bespoke and modular cleanrooms, and related items.

 

For the year ended 31 March 2020, Monmouth Scientific achieved revenues of £6.2 million, and EBIT of £0.4 million (unaudited) and for the six months ended 30 September 2020, the company achieved revenues of £3.7 million and EBIT of £0.8 million (unaudited), adjusted to eliminate non-recurring items and to reflect Monmouth Scientific's ongoing cost base within the Group (year ended 31 March 2020, unaudited statutory profit before tax of £0.28 million).

 

Approximately 80 per cent. of Monmouth Scientific's sales are to UK customers. The COVID-19 pandemic has generated a significant surge in demand for the company's biological safety cabinets which is expected to continue for the rest of its financial year.

 

Based in Bridgwater, Somerset, Monmouth Scientific was founded in 2003 by David & Lisa Pomeroy and employs approximately 65 staff. David will continue to lead the company within the SDI Group.

 

Monmouth Scientific is outgrowing its current premises and is expected, following the Acquisition, to contract for new and larger purpose-built leased premises locally which have already been identified, and which will enable operating efficiency and production expansion.

 

Acquisition rationale

 

The Acquisition is in line with the Group's strategy of acquiring businesses with complementary scientific and technology products, with capable management teams in place and with opportunities to grow further under the SDI Group structure. Monmouth Scientific is expected to join SDI's Sensors and Controls reporting segment. Excluding current COVID-19 led demand, the SDI Board considers that there are long term growth drivers for Monmouth Scientific's products and services.

Consideration for the Acquisition

 

Total consideration is estimated at £5.8 million, excluding cash acquired, and consists of:

· Initial consideration of £2.66 million, of which £2.46 million in cash and £200,000 in SDI ordinary shares ("Ordinary Shares") equating to 230,680 shares issued at 86.7 pence per share, being the average mid-market closing price for the five business days prior to the date of this announcement. The shares issued are subject to a one-year lock-in agreement*;

· A payment in cash shortly after completion, equivalent to the net tangible assets of Monmouth Scientific at completion, currently estimated at £1.6 million and which net tangible assets are estimated to include c.£0.6 million of cash and no bank debt (subject to completion accounts); and

· An earnout cash payment, payable after 31 March 2021, currently estimated at £2.1 million.

 

The total consideration is capped at £6.94 million (including estimated £0.6 million of cash acquired), and this would be payable based on Monmouth Scientific achieving adjusted EBIT for the year to 31 March 2021 in excess of £1.9 million.

The cash consideration will be funded from existing cash resources and from the Group's existing revolving credit facility with HSBC UK Bank. At 31 October 2020, the Group had cash of £3.4 million (unaudited), net debt of £0.3 million (unaudited) (excluding IFRS16 lease liabilities), and £5.0 million of undrawn bank facility.

Issue of new Ordinary Shares and Total Voting Rights

As referred to above, as part of the consideration for the Acquisition, SDI has issued 230,680 new Ordinary Shares. Application will be made to the London Stock Exchange for the 230,680 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 9 December 2020.

The total number of Ordinary Shares in issue is now 98,017,964 and the total number of voting rights is therefore 98,017,964. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries

SDI Group plc 01223 320480

Ken Ford, Chairman

Mike Creedon, CEO

Jon Abell, CFO

www.thesdigroup.net

 

finnCap Ltd 020 7220 0500

Ed Frisby/Kate Bannatyne - Corporate Finance

Andrew Burdis/Sunila de Silva - ECM

 

JW Communications 07818 430877

Julia Wilson - Investor & Public Relations

About SDI Group plc:

SDI designs and manufactures scientific and technology products for use in digital imaging and sensing and control applications including life sciences, healthcare, astronomy, manufacturing, precision optics and art conservation. SDI operates through its company divisions: Atik Cameras, Synoptics, Graticules Optics, Sentek, Astles Control Systems, Applied Thermal Control, MPB Industries, Chell Instruments and Monmouth Scientific.

SDI continues to grow by developing its own technology advancements and by improving its global sales channels, as well as through pursuing strategic, complementary acquisitions. www.thesdigroup.net 

 

 

No statement in this announcement is intended to be a profit forecast or estimate and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

*Lock-in Agreement: No disposals of Ordinary Shares without the prior consent of the Company.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUUAWRRSUURAA
Date   Source Headline
12th Dec 201212:43 pmRNSDirector/PDMR Shareholding
12th Dec 20127:00 amRNSUnaudited Interim Results to 31 October 2012
12th Dec 20127:00 amRNSSynoptics Health: ProReveal product launch update
15th Nov 20124:59 pmRNSHolding(s) in Company
16th Oct 20127:00 amRNSIssue of Equity
11th Sep 20123:20 pmRNSResult of AGM
25th Jul 201212:01 pmRNSDirector/PDMR Shareholding
25th Jul 20128:12 amRNSFinal Results
29th May 201210:05 amRNSDirectorate Change
16th Dec 20117:00 amRNSHalf Yearly Report
15th Sep 20111:52 pmRNSAppointment of Acting Managing Director
1st Sep 20112:04 pmRNSResult of AGM
18th Jul 20115:01 pmRNSNotice of Results
1st Jun 20111:00 pmRNSTrading Update
17th Jan 20117:00 amRNSHalf Yearly Report
10th Dec 20103:48 pmRNSTrading Update
27th Sep 201012:01 pmRNSSector Change
23rd Sep 20103:15 pmRNSResult of AGM
19th Jul 20102:27 pmRNSDirector/PDMR Shareholding
19th Jul 20107:00 amRNSFinal Results
16th Jul 20108:58 amRNSAnalyst Presentation
7th Jul 201012:08 pmRNSNotice of Results
7th Jul 201012:01 pmRNSChange of Adviser
28th Jun 20107:00 amRNSSynbiosis Update
24th May 20107:00 amRNSDirectorate Change
21st May 20107:00 amRNSTrading Update
16th Mar 201012:25 pmRNSDirectorate Changes
2nd Mar 20109:59 amRNSTrading Update
10th Feb 20107:00 amRNSNew Atik Camera
25th Jan 20107:00 amRNSHalf Yearly Report
4th Jan 20104:20 pmRNSDirectorate Change
9th Dec 20091:46 pmRNS12 Months on AIM
21st Oct 200911:21 amRNSResult of AGM
16th Oct 20093:45 pmRNSIssue of Equity
14th Oct 20094:50 pmRNSChange of Adviser
14th Sep 20097:00 amRNSFinal Results
18th Jun 20094:52 pmRNSExercise of Options
7th Apr 20097:00 amRNSTrading Statement
6th Feb 20094:14 pmRNSDirector/PDMR Shareholding
27th Jan 20097:30 amRNSInterim Results
8th Dec 20087:00 amRNSFirst Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.